News in brief: Neoadjuvant therapy adds value in pancreatic cancer; TGA approves dual immunotherapy for mesothelioma; Clinical nutrition guidance for cancer patients

Improved prognosis follows response to neoadjuvant therapy Pancreatic cancer patients who respond to neoadjuvant therapy likely have a favourable disease biology and will progress well following resection. An Australian review of outcomes in 60 patients, with either borderline resectable or locally advanced pancreatic cancer treated with neoadjuvant therapy (NAT) then curative resection, found mean recurrence-free ...

Already a member?

Login to keep reading.

© 2022 the limbic